Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
HIV Clinical Trials
|
November 13, 2009
Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine
Anthony Amoroso, Bruce L Gilliam, Rohit Talwani, et al.
Current Medical Research and Opinion
|
May 28, 2020
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis
Tarik Asselah, Stefan Zeuzem, Nancy Reau, et al.
Clinical and Translational Science
|
September 3, 2011
IL28B genotype does not correlate with HIV control in African Americans
Mohammad M Sajadi, Nahzinine Shakeri, Rohit Talwani, et al.
International Journal of Women'S Health
|
December 11, 2019
Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
Christophe Hézode, Paul Kwo, Jan Sperl, et al.
Hepatology International
|
July 24, 2015
Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C
Shivakumar Narayanan, Kerry Townsend, Thomas Macharia, et al.
Hepatic Medicine : Evidence and Research
|
May 6, 2020
Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
Konstantin Zhdanov, Vasily Isakov, Eduard Burnevich, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 5, 2002
Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy
Rohit Talwani, Oluwatoyin M Falusi, Carlos F Mendes de Leon, et al.
Journal of Gastroenterology
|
January 19, 2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
Stefan Zeuzem, Lawrence Serfaty, John Vierling, et al.
The American Journal of Gastroenterology
|
April 27, 2018
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials
Philippe J Zamor, John Vierling, Reem Ghalib, et al.
Clinical and Molecular Hepatology
|
May 29, 2019
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
Youn Jae Lee, Jeong Heo, Do Young Kim, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
HIV Clinical Trials
|
November 13, 2009
Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine
Anthony Amoroso, Bruce L Gilliam, Rohit Talwani, et al.
Current Medical Research and Opinion
|
May 28, 2020
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis
Tarik Asselah, Stefan Zeuzem, Nancy Reau, et al.
Clinical and Translational Science
|
September 3, 2011
IL28B genotype does not correlate with HIV control in African Americans
Mohammad M Sajadi, Nahzinine Shakeri, Rohit Talwani, et al.
International Journal of Women'S Health
|
December 11, 2019
Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
Christophe Hézode, Paul Kwo, Jan Sperl, et al.
Hepatology International
|
July 24, 2015
Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C
Shivakumar Narayanan, Kerry Townsend, Thomas Macharia, et al.
Hepatic Medicine : Evidence and Research
|
May 6, 2020
Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
Konstantin Zhdanov, Vasily Isakov, Eduard Burnevich, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 5, 2002
Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy
Rohit Talwani, Oluwatoyin M Falusi, Carlos F Mendes de Leon, et al.
Journal of Gastroenterology
|
January 19, 2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
Stefan Zeuzem, Lawrence Serfaty, John Vierling, et al.
The American Journal of Gastroenterology
|
April 27, 2018
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials
Philippe J Zamor, John Vierling, Reem Ghalib, et al.
Clinical and Molecular Hepatology
|
May 29, 2019
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
Youn Jae Lee, Jeong Heo, Do Young Kim, et al.
Page
of 5